Combining Haloperidol and UNC9994 to Treat Schizophrenia in Mice
Author Information
Author(s): Tatiana V Lipina, Huy Giang, Jonathan S Thacker, William C Wetsel, Marc G Caron, Jean Martin Beaulieu, Ali Salahpour, Amy J Ramsey
Primary Institution: University of Toronto
Hypothesis
The combination of haloperidol and UNC9994 will improve schizophrenia-related symptoms in mouse models of NMDAR deficiency.
Conclusion
The dual administration of haloperidol with UNC9994 at low doses represents a promising approach to ameliorate symptoms of schizophrenia.
Supporting Evidence
- Co-administration of haloperidol and UNC9994 reduced hyperactivity in MK-801-treated animals.
- This dual administration effectively reversed PPI deficits and improved cognitive functions in the Y-maze and Puzzle box tests.
- Pharmacological inhibition of NMDAR by MK-801 induced opposite effects on pAkt-S473 and pGSK3β-Ser9 in the PFC and striatum.
- Low doses of haloperidol or UNC9994 alone had modest effects, but their combination showed significant improvements.
Takeaway
Researchers found that giving two drugs together helped mice with schizophrenia-like symptoms feel better and behave more normally.
Methodology
Mice were treated with haloperidol, UNC9994, or their combination, and tested in various behavioral assays to assess schizophrenia-related symptoms.
Potential Biases
Potential bias in the selection of biochemical markers and the limited sample size for some treatments.
Limitations
The study only used two brain areas and a limited number of biochemical markers, which may not capture the full effects of the treatments.
Participant Demographics
Mice of mixed genotypes (wild type and Grin1 knockdown) were used in the study.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website